Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say ...

"Analysis shows Yeztugo approval a ‘momentous step’ for HIV prevention" was originally created and published by ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

A new U.N. AIDS agency report says the sudden withdrawal of U.S. funding has caused a “systemic shock” to the global effort ...

A twice-yearly injection could help Australia eliminate HIV, but experts are sounding the alarm over its prohibitive cost.

As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...

A report released by the United Nations revealed that US funding cuts could significantly increase the mortality rate to four ...

Gilead Sciences (NasdaqGS:GILD) recently announced a partnership with the Global Fund to supply lenacapavir for HIV ...

The UN says the withdrawal of US funding for the global HIV fight could lead to more than 4 million AIDS-related deaths and over 6 million additional HIV infections by 2029 if not replaced.

Global deaths from AIDS have dropped to their lowest levels in more than 30 years, in part due to efforts to fight HIV. But U ...

UN says if US funding for HIV programs is not replaced, millions more will die by 2029 ... Last month, the U.S. Food and Drug Administration approved the drug, called Yeztugo, ...